» Articles » PMID: 33888394

Concerning CT Features Predict Outcome of Treatment in Patients with Malignant Peritoneal Mesothelioma

Overview
Publisher Elsevier
Date 2021 Apr 23
PMID 33888394
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Malignant peritoneal mesothelioma is an aggressive local-regional disease with dissemination to all parts of the abdomen and pelvis at the time of diagnosis. Recently, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used and improved survival was documented with this local-regional treatment strategy.

Method: Concerning CT features were described that were specific for malignant peritoneal mesothelioma. The incidence of concerning radiologic features and their impact on survival was determined. The prognostic assessment of concerning CT features was compared to the peritoneal cancer index (PCI) and the completeness of cytoreduction score (CC score).

Results: One hundred patients with a preoperative CT were evaluated by 11 concerning CT features. The incidence of these CT features varied between 5% and 41%. Nine of the 11 CT features statistically significantly predicted a reduced survival in these patients treated in a uniform manner. When concerning radiologic features were grouped as none, a single feature or two or more features, a significant composite analysis was achieved with p < 0.001. The prognostic information from concerning CT features compared favorably with the prognostic implications of PCI and CC score.

Conclusions: The availability of the concerning CT features to predict prognosis at the initiation of treatments for malignant peritoneal mesothelioma shows that this radiologic assessment may be of great value to the clinician in planning a treatment strategy for an individual patient.

Citing Articles

Transfer learning approach in pre-treatment CT images to predict therapeutic response in advanced malignant pleural mesothelioma.

Fanizzi A, Catino A, Bove S, Comes M, Montrone M, Sicolo A Front Oncol. 2024; 14:1432188.

PMID: 39351354 PMC: 11439621. DOI: 10.3389/fonc.2024.1432188.


It Is What the Surgeon Does Not See That Kills the Patient.

Sugarbaker P J Clin Med. 2024; 13(8).

PMID: 38673511 PMC: 11051342. DOI: 10.3390/jcm13082238.


Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma.

Chen Y, Du X, Gao Y, Wu H, Zhao H, Su Y Cancer Control. 2023; 30:10732748231220805.

PMID: 38092371 PMC: 10722924. DOI: 10.1177/10732748231220805.


Selection Factors for Treatment and Stratification of Rare Abdominal or Pelvic Tumors with Peritoneal Metastases.

Sugarbaker P Indian J Surg Oncol. 2023; 14(Suppl 1):7-14.

PMID: 37359915 PMC: 10284755. DOI: 10.1007/s13193-022-01593-9.


Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma.

Kusamura S, Baratti D, De Simone M, Pasqual E, Ansaloni L, Marrelli D Cancers (Basel). 2023; 15(3).

PMID: 36765620 PMC: 9913096. DOI: 10.3390/cancers15030662.